An Expert Report on Mirabegron (DB08893): A Comprehensive Monograph

1.0 Executive Summary

Mirabegron (DrugBank ID: DB08893) is a first-in-class, orally active, selective beta-3 adrenergic receptor (β3-AR) agonist. It represents a significant therapeutic advancement in the management of urological storage disorders, offering a distinct mechanism of action compared to the long-standing class of antimuscarinic agents. Developed by Astellas Pharma and marketed under brand names including Myrbetriq®, Betmiga®, and Betanis®, Mirabegron is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Its approval has been extended to include treatment of neurogenic detrusor overactivity (NDO) in pediatric patients and for use in combination with the antimuscarinic solifenacin succinate for refractory OAB in adults.[1]

The primary pharmacodynamic effect of Mirabegron is the relaxation of the detrusor smooth muscle during the bladder's storage phase. This is achieved through selective activation of β3-ARs, which are highly expressed in the bladder, leading to an increase in intracellular cyclic adenosine monophosphate (cAMP).[4] This mechanism increases the functional capacity of the bladder, thereby alleviating the core symptoms of OAB. Crucially, Mirabegron lacks significant antimuscarinic activity, which is the pharmacological basis for its principal clinical advantage: a more favorable tolerability profile than traditional anticholinergic drugs, with a markedly lower incidence of dry mouth and constipation.[1]

Clinical evidence from extensive Phase 3 trials demonstrates that Mirabegron has efficacy comparable to that of standard antimuscarinic agents like solifenacin and tolterodine but offers a superior balance of efficacy and tolerability.[7] This profile establishes it as a valuable first-line option for many patients, particularly the elderly or those with contraindications to anticholinergics, and as a definitive second-line therapy for patients who are intolerant to antimuscarinic side effects.

The safety profile of Mirabegron is well-defined but distinct from that of antimuscarinics. The primary safety concerns are dose-dependent increases in blood pressure and heart rate, necessitating periodic monitoring, especially in hypertensive patients. The drug is not recommended for use in individuals with severe uncontrolled hypertension.[5] Other notable risks include rare but serious angioedema and a potential for urinary retention in patients with bladder outlet obstruction.[10] From a pharmacokinetic perspective, Mirabegron is a moderate inhibitor of the cytochrome P450 2D6 (CYP2D6) enzyme, creating a significant potential for drug-drug interactions with CYP2D6 substrates, particularly those with a narrow therapeutic index.[1]

In summary, Mirabegron has secured a critical position in the clinical armamentarium for bladder dysfunction. Its unique mechanism, proven efficacy, and favorable tolerability have addressed a long-standing unmet need in OAB management, providing a vital alternative for patients and establishing a new paradigm for combination therapy in refractory cases.

2.0 Introduction: A New Therapeutic Class for Bladder Dysfunction

2.1 The Pathophysiology of Overactive Bladder (OAB) and Neurogenic Detrusor Overactivity (NDO)

Overactive Bladder (OAB) is a highly prevalent and often distressing symptom complex, defined by the International Continence Society as the presence of urinary urgency, which is typically accompanied by increased urinary frequency and nocturia, with or without urge urinary incontinence.[12] It is crucial to recognize that OAB is not a discrete disease entity but rather a clinical syndrome that can arise from various underlying etiologies.[12] The central pathophysiological feature of OAB is the involuntary contraction of the detrusor muscle, the smooth muscle layer of the bladder wall, during the bladder's storage or filling phase.[5] Normal micturition is regulated by a complex interplay between the sympathetic and parasympathetic nervous systems. During bladder filling, sympathetic stimulation promotes detrusor relaxation and bladder neck contraction, allowing for low-pressure urine storage. During voiding, parasympathetic stimulation, mediated by acetylcholine (ACh) release, triggers detrusor contraction.[6] In OAB, this control is disrupted, leading to inappropriate detrusor contractions that generate the hallmark sensation of urgency.[5] These contractions are primarily driven by the parasympathetic nervous system, with ACh acting on M2 and M3 muscarinic receptor subtypes on detrusor muscle cells.[6]

Neurogenic Detrusor Overactivity (NDO) is a related but distinct condition characterized by bladder dysfunction that stems from a confirmed neurological impairment, such as a spinal cord injury, multiple sclerosis, or spina bifida.[1] While the end result is also involuntary detrusor contractions, the origin is a disruption in the nerve signals between the brain, spinal cord, and bladder.

2.2 Limitations of Traditional Antimuscarinic Therapy

For over three decades, the cornerstone of pharmacological management for OAB was the antimuscarinic (or anticholinergic) class of drugs.[15] These agents, such as oxybutynin, tolterodine, and solifenacin, exert their therapeutic effect by competitively blocking the action of acetylcholine at M2 and M3 muscarinic receptors on the detrusor muscle, thereby inhibiting involuntary bladder contractions and increasing bladder capacity.[1]

Despite their established efficacy, the clinical utility of antimuscarinics has been consistently hampered by a significant treatment-limiting side-effect profile.[1] Muscarinic receptors are not confined to the bladder; they are widely distributed throughout the body, including in the salivary glands, gastrointestinal tract, ciliary body of the eye, and central nervous system. Consequently, systemic blockade of these receptors leads to a constellation of well-known adverse effects, including dry mouth (xerostomia), constipation, blurred vision, and central nervous system effects such as somnolence, confusion, and cognitive impairment.[7] These side effects are often bothersome enough to cause poor patient tolerance, low adherence to therapy, and high rates of treatment discontinuation, frequently within the first few months of initiation.[7] This created a substantial unmet clinical need for an effective OAB treatment with a different mechanism and a more favorable tolerability profile.

2.3 Mirabegron: The First-in-Class β3-Adrenergic Agonist

The advent of Mirabegron, developed by Astellas Pharma, marked a paradigm shift in the pharmacological approach to OAB.[15] Approved by the U.S. Food and Drug Administration (FDA) in 2012, it was the first clinically available β3-adrenergic agonist for the treatment of OAB, representing the first new oral treatment class for the condition in over 30 years.[1]

The introduction of Mirabegron was not merely an incremental improvement but a fundamental change in therapeutic strategy. It shifted the pharmacological target away from the parasympathetic pathway responsible for bladder contraction to the sympathetic pathway involved in bladder relaxation. The human bladder expresses a high concentration of β3-adrenergic receptors, which, when stimulated, promote detrusor muscle relaxation.[6] By selectively targeting this pathway, Mirabegron was designed to improve the bladder's storage capacity without the systemic muscarinic blockade that plagued older therapies. The primary clinical value of Mirabegron, as borne out by extensive clinical trials, lies not in demonstrating superior efficacy over antimuscarinics, but in offering a comparable level of efficacy with a significantly improved tolerability profile. This distinct risk-benefit balance directly addresses the principal limitations of antimuscarinic therapy, providing a crucial alternative for patients who are intolerant to or have contraindications for the older class of drugs.

3.0 Physicochemical Profile and Pharmaceutical Formulations

3.1 Chemical Structure and Nomenclature

Mirabegron is classified chemically as a monocarboxylic acid amide and is a member of the 1,3-thiazole and ethanolamine structural families.[1] It is obtained through the formal condensation of the carboxyl group of 2-amino-1,3-thiazol-4-ylacetic acid with the anilino group of (1R)-2-{[2-(4-aminophenyl)ethyl]amino}-1-phenylethanol.[1]

Its formal International Union of Pure and Applied Chemistry (IUPAC) name is 2-(2-amino-1,3-thiazol-4-yl)-N-amino]ethyl]phenyl]acetamide.[1] The molecular formula is

C21​H24​N4​O2​S.[1] For structural informatics and database cross-referencing, its key identifiers are:

• InChI: InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 [1]
• InChIKey: PBAPPPCECJKMCM-IBGZPJMESA-N [1]
• SMILES: C1=CC=C(C=C1)[C@H](CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O [1]

3.2 Physical and Chemical Properties

Mirabegron presents as a white to light-yellow or off-white crystalline solid or powder.[19] It has a molecular weight of 396.51 g/mol.[9] The reported melting point varies slightly across sources, with ranges cited as 138-140°C, 141.0-145.0°C, and a specific value of 143°C.[19]

The compound's solubility profile is a critical determinant of its pharmaceutical formulation. It is considered practically insoluble in water, with a measured solubility of 0.082 g/L.[21] It exhibits slight solubility in organic solvents such as methanol, ethanol, and chloroform.[20] Due to its sensitivity to air and heat, Mirabegron requires refrigerated storage (0-10°C) under an inert atmosphere to maintain stability.[20]

3.3 Available Formulations

The intrinsic properties of Mirabegron, particularly its long elimination half-life of approximately 50 hours in adults and its poor water solubility, directly guided its development into extended-release dosage forms suitable for once-daily administration.[1] An immediate-release formulation would risk incomplete and variable absorption, while also potentially causing sharp peaks in plasma concentration (Cmax) that could exacerbate dose-dependent side effects like hypertension.[25] The extended-release technology mitigates these issues by ensuring a slow, controlled dissolution and absorption of the drug, which flattens the pharmacokinetic profile, maintains therapeutic concentrations over 24 hours, and enhances both efficacy and safety.

Two primary formulations are commercially available:

• Prolonged-Release Tablets: Marketed as Myrbetriq® or Betmiga®, these tablets are available in 25 mg (oval, brown, debossed with Astellas logo and "325") and 50 mg (oval, yellow, debossed with Astellas logo and "355") strengths.[10] To preserve the integrity of the controlled-release mechanism, these tablets must be swallowed whole with water and must not be crushed, divided, or chewed.[10]
• Prolonged-Release Granules for Oral Suspension: Marketed as Myrbetriq Granules®, this formulation provides a concentration of 8 mg/mL when reconstituted.[13] It was specifically developed and approved to facilitate accurate, weight-based dosing for pediatric patients aged 3 years and older being treated for NDO.[1]

Table 1: Chemical and Physical Identifiers of Mirabegron
Property	Value	Source(s)
CAS Number	223673-61-8	1
DrugBank ID	DB08893	1
Molecular Formula	C21​H24​N4​O2​S	1
Molecular Weight	396.51 g/mol	9
IUPAC Name	2-(2-amino-1,3-thiazol-4-yl)-N-amino]ethyl]phenyl]acetamide	1
Appearance	White to light yellow/off-white solid or powder	19
Melting Point	138-145 °C (range from various sources)	19
Solubility in Water	Insoluble (0.082 g/L)	21
Solubility (Organic)	Slightly soluble in methanol, ethanol, chloroform	20
InChIKey	PBAPPPCECJKMCM-IBGZPJMESA-N	1

4.0 Pharmacodynamics: The Mechanism of β3-Adrenergic Agonism

4.1 Selective Activation of the β3-Adrenergic Receptor

The therapeutic action of Mirabegron is rooted in its function as a potent and selective agonist of the human β3-adrenergic receptor (β3-AR).[4] The human urinary bladder is an ideal target for such an agent, as quantitative PCR studies have revealed that the β3-AR subtype constitutes more than 95% of the total β-adrenergic receptor mRNA present in the detrusor muscle.[6] This high density and specificity provide a strong rationale for targeted therapy.

Mirabegron exhibits remarkable selectivity for the β3-AR. In vitro biochemical assays demonstrate its potent agonistic activity at the human β3-AR, with a half-maximal effective concentration (EC50​) of approximately 22.4 nM.[20] In stark contrast, its activity at β1-AR and β2-ARs is negligible at therapeutic concentrations, with

EC50​ values exceeding 10,000 nM.[20] Clinically, evidence of β1-AR stimulation, such as a significant increase in heart rate, is generally observed only at supratherapeutic doses of 200 mg or higher, well above the recommended maximum daily dose of 50 mg.[5] This high degree of selectivity is a cornerstone of the drug's design, enabling a therapeutic window where effects on the bladder are maximized while minimizing off-target cardiovascular effects commonly associated with non-selective beta-agonists.

4.2 Downstream Signaling: G-Protein Coupling and Cyclic AMP (cAMP) Pathway

The β3-AR is a G-protein coupled receptor (GPCR), specifically linked to the stimulatory G-protein, Gs.[4] Upon binding of Mirabegron to the β3-AR, the Gs protein is activated. This activation, in turn, stimulates the membrane-bound enzyme adenylyl cyclase.[4] The primary function of adenylyl cyclase is to catalyze the conversion of adenosine triphosphate (ATP) into the second messenger molecule, cyclic adenosine monophosphate (cAMP).[4] The resulting elevation in intracellular cAMP concentration is the key biochemical event that initiates the downstream signaling cascade responsible for smooth muscle relaxation.[6] While the cAMP pathway is the principal accepted mechanism, some evidence also suggests that β-AR stimulation may contribute to relaxation by activating large-conductance calcium-activated potassium (

BKCa​) channels, which would lead to hyperpolarization of the muscle cell membrane and reduced contractility.[18]

4.3 Physiological Effect: Detrusor Muscle Relaxation and Increased Bladder Capacity

The ultimate physiological consequence of β3-AR activation by Mirabegron is the relaxation of the detrusor smooth muscle.[1] This effect is most relevant during the storage phase of the micturition (fill-void) cycle.[5] By relaxing the bladder wall, Mirabegron increases the functional capacity of the bladder, allowing it to store a larger volume of urine at low pressure.[4] This increased storage capacity directly addresses the core symptoms of OAB by reducing the frequency of urination, lessening the sensation of urgency, and decreasing the number of urge incontinence episodes.[4]

Furthermore, research suggests that Mirabegron may also exert a beneficial effect by suppressing non-voiding contractions, or "micromotions," of the bladder.[4] These subtle, spontaneous contractions during the filling phase are thought to be a significant source of afferent nerve signaling that contributes to the sensation of urgency, and their inhibition may be an additional mechanism by which Mirabegron provides symptomatic relief.[18]

4.4 Receptor Selectivity and the Absence of Antimuscarinic Effects

A defining pharmacodynamic characteristic of Mirabegron is its lack of significant affinity for and activity at muscarinic receptors.[1] This is the fundamental distinction between Mirabegron and the entire class of anticholinergic agents. By avoiding the muscarinic pathway, Mirabegron circumvents the mechanism responsible for the hallmark side effects of anticholinergic drugs. This selectivity is the direct pharmacological basis for its significantly more favorable tolerability profile, particularly the much lower incidence of dry mouth, constipation, blurred vision, and cognitive side effects that often limit the use of antimuscarinics.[7]

4.5 Emerging Pharmacodynamic Insights: Effects on Brown Adipose Tissue and Metabolism

The pharmacodynamic profile of Mirabegron extends beyond the urinary system. β3-ARs are also highly expressed in brown adipose tissue (BAT), the primary organ for nonshivering thermogenesis in mammals.[9] Studies in both animals and humans have demonstrated that Mirabegron is an effective activator of BAT.[31] Activation of β3-ARs in brown adipocytes stimulates the expression of uncoupling protein 1 (UCP1), which uncouples mitochondrial respiration from ATP synthesis, dissipating energy as heat.[31] This process consumes glucose and lipids, leading to increased energy expenditure.

This discovery has profound implications, suggesting that Mirabegron is not merely a "bladder drug" but a systemic β3-AR agonist with potential pleiotropic metabolic effects. This has spurred significant research interest into the potential repurposing of Mirabegron or the development of new β3-AR agonists for the treatment of metabolic disorders such as obesity and type 2 diabetes.[9] For instance, preclinical studies in mice have shown that combining Mirabegron with metformin resulted in greater weight loss than either agent alone, highlighting a potential synergistic effect.[9] This opens up an entirely new avenue of investigation, raising questions about whether long-term Mirabegron use for OAB might confer unintended but potentially beneficial metabolic effects in patients, a third-order question that warrants clinical exploration.

5.0 Pharmacokinetics: A Comprehensive ADME Profile

The pharmacokinetic profile of Mirabegron is characterized by oral absorption from an extended-release formulation, extensive tissue distribution, complex metabolism involving multiple enzymatic pathways, and elimination through both renal and fecal routes. This profile has significant clinical implications for dosing, drug interactions, and use in special populations.

5.1 Absorption and Bioavailability

Following oral administration of the extended-release tablet, Mirabegron reaches maximum plasma concentrations (Tmax​) in approximately 3.5 hours.[12] Its absolute bioavailability is dose-dependent, increasing from 29% at the 25 mg dose to 35% at the 50 mg dose, suggesting that absorption processes become more efficient at the higher therapeutic dose.[25]

The pharmacokinetics of Mirabegron are non-linear at doses above the therapeutic range. The area under the concentration-time curve (AUC) and maximum concentration (Cmax​) increase in a manner that is more than dose-proportional.[25] For example, doubling the dose from 50 mg to 100 mg results in a 2.6-fold increase in AUC and a 2.9-fold increase in

Cmax​.[25] This non-linearity underscores the importance of adhering to recommended dosing and not exceeding the 50 mg maximum daily dose.

In adults, the tablet can be administered with or without food, as food does not significantly impact its overall exposure.[14] However, for pediatric patients receiving the granule suspension, administration

with food is recommended to lower the risk of side effects such as tachycardia.[13] Steady-state plasma concentrations are typically achieved within 7 days of initiating once-daily dosing.[25]

5.2 Distribution, Volume of Distribution, and Plasma Protein Binding

Mirabegron undergoes extensive distribution into body tissues, which is reflected by its large apparent steady-state volume of distribution (Vd​) of approximately 1670 L following intravenous administration.[20] This value, far exceeding total body water, indicates significant partitioning of the drug from the plasma into peripheral tissues. In human plasma, Mirabegron is moderately bound to proteins (approximately 71%), primarily to albumin and alpha-1 acid glycoprotein.[1]

5.3 Metabolism: Role of CYP450 Enzymes, UGTs, and Other Pathways

Mirabegron is subject to extensive metabolism via several parallel pathways, including amide hydrolysis, oxidative metabolism, and direct glucuronidation.[20] Despite this extensive biotransformation, the unchanged parent drug remains the major circulating component in plasma following oral administration.[25]

The oxidative metabolism of Mirabegron is mediated by two key cytochrome P450 isoenzymes: CYP3A4 and CYP2D6.[1] The conjugation reactions (glucuronidation) are carried out by UDP-glucuronosyltransferase (UGT) enzymes, specifically UGT2B7, UGT1A3, and UGT1A8.[25] Other enzymes, including butylcholinesterase and alcohol dehydrogenase, are also thought to contribute to its metabolism.[25]

This complex metabolic profile creates a high potential for drug-drug interactions. A critical pharmacokinetic property of Mirabegron is that it acts as a moderate inhibitor of CYP2D6.[1] This dual role—being both a substrate for multiple enzymes and an inhibitor of a key enzyme—is a central consideration in its clinical use. Its inhibitory action on CYP2D6 means it can significantly increase the plasma concentrations of co-administered drugs that are primarily metabolized by this enzyme, a point of major clinical significance detailed in Section 9.0.

In individuals who are genetically deficient in CYP2D6 activity (CYP2D6 poor metabolizers), the mean Cmax​ and AUC of Mirabegron are approximately 16-17% higher compared to extensive metabolizers. This modest increase is not considered clinically significant enough to warrant routine genetic testing or a priori dose adjustments.[38]

5.4 Excretion and Elimination Half-Life

Mirabegron and its metabolites are eliminated from the body through both the kidneys and the liver. Following administration of a radiolabeled dose, approximately 55% of the radioactivity is recovered in the urine and 34% is recovered in the feces.[9] Renal elimination of the parent drug accounts for about 25% of the total dose and occurs through a combination of glomerular filtration and active tubular secretion.[20] The active secretion is mediated by organic cation transporters (OCT).

The terminal elimination half-life (t1/2​) of Mirabegron is notably long, which supports the once-daily dosing regimen.

• In adults: The mean elimination half-life is approximately 50 hours.[20]
• In pediatric patients: The elimination is faster, with a mean half-life of approximately 26-31 hours.[25]

5.5 Pharmacokinetic Variability in Special Populations

The clearance of Mirabegron is significantly affected by both renal and hepatic function, necessitating dose adjustments in patients with organ impairment.

• Renal Impairment: As renal function declines, the exposure (AUC) to Mirabegron increases. For patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m2), the maximum recommended daily dose is reduced to 25 mg. The use of Mirabegron is not recommended in patients with end-stage renal disease (eGFR < 15 mL/min/1.73 m2) or those requiring hemodialysis.[10]
• Hepatic Impairment: Similarly, exposure increases with the severity of liver disease. For patients with moderate hepatic impairment (Child-Pugh Class B), the maximum daily dose is 25 mg. Its use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C).[10]

Table 2: Summary of Key Pharmacokinetic Parameters in Adult and Pediatric Populations
Parameter	Adult Population	Pediatric Population (3 to <18 years)
Formulation	Extended-Release Tablet	Extended-Release Granules for Suspension
Absolute Bioavailability	29% (25 mg dose) to 35% (50 mg dose) 25	Not specifically stated, but dosing is weight-based to achieve target exposures.
Time to Peak (Tmax​)	~3.5 hours 12	~4-5 hours 25
Elimination Half-Life (t1/2​)	~50 hours 20	~26-31 hours 25
Volume of Distribution (Vd​)	~1670 L 20	Proportional to body weight, higher relative to adults 12
Plasma Protein Binding	~71% 12	Not specifically stated, presumed similar.
Food Effect	No clinically significant effect 29	Recommended to be taken with food 13

6.0 Clinical Efficacy in Approved Indications

6.1 Monotherapy for Overactive Bladder in Adults

Mirabegron is formally indicated for the symptomatic treatment of OAB in adults, including the management of urge urinary incontinence, urgency, and urinary frequency.[1] Its efficacy was established in a series of large, multinational, randomized, placebo-controlled Phase 3 clinical trials involving over 10,000 patients.[15]

In these pivotal 12-week studies, both the 25 mg and 50 mg once-daily doses of Mirabegron demonstrated statistically significant and clinically meaningful improvements in the co-primary efficacy endpoints compared to placebo.[6] For instance, data submitted for its initial approval showed that treatment with Mirabegron 50 mg reduced the mean number of incontinence episodes by 1.49 per 24 hours (from a baseline of 2.71) and the mean number of micturitions by 1.75 per 24 hours (from a baseline of 11.70). These reductions were statistically significant versus the changes observed with placebo.[15] The therapeutic effect of Mirabegron is typically apparent within the first few weeks of treatment, with maximal efficacy often observed by 8 weeks.[10]

6.2 Treatment of Neurogenic Detrusor Overactivity in Pediatric Patients

In March 2021, the FDA expanded the approved use of Mirabegron to include the treatment of NDO in pediatric patients aged 3 years and older.[1] This indication addresses a significant need in a vulnerable population where bladder dysfunction is secondary to neurological conditions. The approval was specifically for a new formulation, prolonged-release granules for oral suspension, to allow for accurate weight-based dosing.[13] The efficacy in this population was demonstrated in a clinical study involving 86 children and adolescents. The primary measure of effectiveness was the change in maximum cystometric capacity (MCC), which is the volume of urine the bladder can comfortably hold. After 24 weeks of treatment, patients receiving Mirabegron showed a mean increase in MCC of approximately 87 mL, indicating an improved ability of the bladder to store urine.[28]

6.3 Combination Therapy with Solifenacin for Refractory OAB

A major evolution in the management of OAB was the FDA approval in May 2018 for the use of Mirabegron in combination with the M3-selective antimuscarinic agent, solifenacin succinate.[2] This approval provides an evidence-based option for patients who have an inadequate response to monotherapy with either agent alone.[10]

This strategy is built upon a strong pharmacological rationale of complementary mechanisms of action. Mirabegron promotes detrusor relaxation via the sympathetic β3-AR pathway, while solifenacin inhibits involuntary detrusor contractions by blocking the parasympathetic M3 muscarinic pathway.[1] This dual-pathway approach offers the potential for an additive therapeutic effect.

The efficacy of this combination was rigorously established in large-scale clinical trials, including the SYNERGY I & II and BESIDE studies.[3] These trials demonstrated that combination therapy with Mirabegron and solifenacin was statistically superior to monotherapy with either drug alone in improving key OAB symptoms, such as the mean number of incontinence episodes, micturitions, and urgency episodes per 24 hours.[3] Importantly, this enhanced efficacy was achieved without a clinically meaningful increase in the overall incidence of adverse events, establishing the combination as a valuable and well-tolerated third-line treatment strategy before consideration of more invasive procedures like onabotulinumtoxinA injections or sacral neuromodulation.

6.4 Investigational Uses

The therapeutic potential of Mirabegron may extend beyond its currently approved indications. There is ongoing research into its utility for other urological conditions. Notably, a clinical trial (NCT05617664) is actively recruiting participants to evaluate the efficacy of Mirabegron 25 mg for the treatment of primary nocturnal enuresis, commonly known as bedwetting, in adults.[45] The rationale for this investigation likely stems from Mirabegron's established ability to increase bladder capacity, which could be beneficial in preventing nocturnal voiding.

7.0 Analysis of Comparative Clinical Evidence

A comprehensive assessment of Mirabegron's place in therapy requires a detailed analysis of its performance relative to placebo, the established class of anticholinergic agents, and newer drugs within its own class. The collective evidence paints a clear picture of a drug defined more by its favorable tolerability profile than by superior efficacy.

7.1 Superiority to Placebo

The efficacy of Mirabegron is unequivocally established against placebo. The initial regulatory approvals in the US and Europe were based on a robust program of three large, 12-week, randomized, double-blind Phase 3 studies (e.g., SCORPIO, ARIES, CAPRICORN).[15] Across these trials, both the 25 mg and 50 mg once-daily doses of Mirabegron consistently demonstrated statistically significant superiority over placebo in reducing the co-primary endpoints of mean change from baseline in incontinence episodes and micturition frequency per 24 hours.[15]

7.2 Head-to-Head Comparisons with Anticholinergic Agents

Direct comparisons with the former standard of care, anticholinergic drugs, are crucial for positioning Mirabegron in clinical practice.

• Efficacy: Multiple meta-analyses and head-to-head trials have consistently concluded that Mirabegron demonstrates comparable efficacy to widely used anticholinergics, including solifenacin and tolterodine.[7] On primary endpoints such as reductions in micturitions, urgency episodes, and incontinence, Mirabegron is generally considered non-inferior, but not superior, to these agents. This finding implies that for a patient who is responding well to and tolerating an anticholinergic, there is little efficacy-based rationale for switching to Mirabegron.
• Tolerability: The key differentiator and primary advantage of Mirabegron lies in its tolerability profile. By avoiding the muscarinic receptor pathway, Mirabegron is associated with a significantly lower incidence of classic anticholinergic side effects. Systematic reviews and meta-analyses consistently report that patients treated with Mirabegron experience significantly less dry mouth and constipation compared to those on anticholinergics. The incidence of dry mouth with Mirabegron is often statistically indistinguishable from that of placebo.[7] This superior tolerability is the principal driver for its use as an alternative to antimuscarinics.
• Patient Preference and Adherence: The improved tolerability profile is hypothesized to translate into better patient persistence and adherence. Some studies support this, showing higher adherence rates for Mirabegron over a 12-month period.[7] However, other large meta-analyses have found comparable adherence rates between the two classes, suggesting that factors beyond side effects, such as cost and perceived efficacy, also play a significant role in long-term use.[8]

7.3 Comparative Efficacy and Safety versus Other β3-Agonists (Vibegron)

The introduction of a second β3-agonist, Vibegron (Gemtesa®), has prompted direct comparisons to further refine the role of this drug class.

• Efficacy: Head-to-head randomized controlled trials comparing Mirabegron 50 mg and Vibegron 75 mg have generally found no statistically significant difference in their ability to improve OAB symptoms. Analyses of changes in the Overactive Bladder Symptom Score (OABSS) and its individual components (frequency, nocturia, urgency, incontinence) show similar magnitudes of effect for both drugs.[17]
• Safety and Practical Differences: While the overall safety profiles are broadly similar, there are key distinctions that can influence clinical decision-making. Vibegron is not associated with a clinically significant increase in blood pressure and is not an inhibitor of CYP2D6, which may make it a preferable option for patients with pre-existing hypertension or those on complex medication regimens involving CYP2D6 substrates.[47] Conversely, at least one comparative trial reported a higher rate of overall adverse events with Vibegron than with Mirabegron.[44] Another practical difference is that Vibegron tablets may be crushed and mixed with applesauce for patients with dysphagia, whereas Mirabegron extended-release tablets must be swallowed whole.[47]

The choice between Mirabegron and an anticholinergic is therefore a classic clinical trade-off. It requires a personalized assessment, weighing the adrenergic risks of Mirabegron (hypertension) against the anticholinergic risks of the alternative (dry mouth, constipation, cognitive effects). Mirabegron's role is not to replace anticholinergics universally, but to provide a mechanistically distinct alternative that allows for more individualized and better-tolerated management of OAB.

Table 3: Summary of Pivotal Phase III Clinical Trials vs. Placebo and Anticholinergics
Trial (Identifier)	Comparator(s)	Patient Population	Primary Endpoints	Key Efficacy Results (Change from Baseline)	Key Tolerability Finding (Incidence of Dry Mouth)
SCORPIO (178-CL-046) 15	Placebo, Tolterodine ER 4 mg	Adults with OAB (US)	Change in micturitions/24h; Change in incontinence episodes/24h	Mira 50mg: -1.8 micturitions; -1.5 episodes. Statistically significant vs. placebo.	Mira 50mg: 2.8% vs. Placebo: 2.3% vs. Tolterodine: 10.1%
ARIES (178-CL-047) 15	Placebo	Adults with OAB (US)	Change in micturitions/24h; Change in incontinence episodes/24h	Mira 50mg: -1.9 micturitions; -1.5 episodes. Statistically significant vs. placebo.	Mira 50mg: 3.4% vs. Placebo: 2.0%
CAPRICORN (178-CL-049) 16	Placebo	Adults with OAB (Europe/Australia)	Change in micturitions/24h; Change in incontinence episodes/24h	Mira 50mg: -1.9 micturitions; -1.6 episodes. Statistically significant vs. placebo.	Mira 50mg: 3.0% vs. Placebo: 2.1%
BESIDE (NCT01908829) 3	Solifenacin 5 mg monotherapy	Adults with OAB inadequately treated with solifenacin	Change in micturitions/24h; Change in incontinence episodes/24h	Combination therapy (Mira 50mg + Soli 5mg) was statistically superior to solifenacin 5mg monotherapy on all primary endpoints.	Combination: 9.3% vs. Soli 5mg: 6.5%

8.0 Comprehensive Safety and Tolerability Assessment

The safety profile of Mirabegron is well-characterized through extensive clinical trials and over a decade of post-marketing surveillance. Its adverse event profile is fundamentally different from that of antimuscarinic agents, trading cholinergic side effects for adrenergic ones.

8.1 Analysis of Adverse Events from Clinical Trials

Data pooled from Phase 3 clinical trials provide a clear picture of the most common adverse reactions associated with Mirabegron.[9]

• Very Common (>10% incidence): The most frequently reported adverse event in some trials, particularly at the 25 mg dose, was elevated blood pressure (hypertension), with an incidence of 11.3% for the 25 mg dose versus 7.6% for placebo in pooled data.[9]
• Common (1–10% incidence): A range of common adverse events have been consistently reported. These include:
• Nasopharyngitis (common cold symptoms): 3.5% to 3.9% [9]
• Urinary Tract Infection (UTI): 2.9% to 4.2% [9]
• Headache: 2.1% to 3.2% [9]
• Tachycardia (fast heart rate) [9]
• Gastrointestinal effects: Constipation and dry mouth, although the incidence of dry mouth is significantly lower than with anticholinergics [9]
• Musculoskeletal effects: Back pain and joint pain [9]
• Uncommon/Rare (<1% incidence): Less frequent but potentially serious adverse events include atrial fibrillation, palpitations, blurred vision, indigestion (dyspepsia), and elevations in liver enzymes (AST, ALT, GGTP).[9]

8.2 Warnings and Precautions

The official prescribing information for Mirabegron includes several important warnings and precautions that guide its safe use.

• Increases in Blood Pressure: As a β-adrenergic agonist, Mirabegron can cause dose-dependent increases in both systolic and diastolic blood pressure. This effect is a primary safety concern. Periodic blood pressure monitoring is recommended for all patients, especially those with pre-existing hypertension. Mirabegron is explicitly not recommended for use in patients with severe uncontrolled hypertension, defined as a systolic blood pressure of ≥180 mmHg and/or a diastolic blood pressure of ≥110 mmHg.[5]
• Urinary Retention: Although Mirabegron works by relaxing the detrusor, there is a risk of urinary retention, particularly in certain patient populations. Caution should be exercised when administering Mirabegron to patients with clinically significant bladder outlet obstruction (BOO) (e.g., due to benign prostatic hyperplasia) or to patients who are concurrently taking antimuscarinic medications for OAB. These patients should be monitored for signs and symptoms of urinary retention, such as difficulty urinating or a weak stream.[9]
• Angioedema: Rare but potentially life-threatening cases of angioedema of the face, lips, tongue, and/or larynx have been reported with Mirabegron use. This swelling can occur after the first dose or after multiple doses. Angioedema involving the upper airway can compromise breathing and constitutes a medical emergency. If any signs of angioedema occur, Mirabegron must be discontinued immediately, and appropriate measures must be taken to ensure a patent airway.[9]

8.3 Insights from Post-Marketing Surveillance and Real-World Data

Post-marketing surveillance provides valuable insights into the real-world safety profile of a drug. An analysis of the FDA Adverse Event Reporting System (FAERS) database from 2012 to 2023, encompassing over 18,000 reports associated with Mirabegron, confirmed the known common adverse events identified in clinical trials, such as hypertension, urinary retention, atrial fibrillation, and tachycardia.[49]

This pharmacovigilance study also identified several new, unexpected, and serious potential safety signals, including arrhythmia, palpitations, dementia, transient ischemic attack (TIA), Parkinson's disease, and ANCA-positive vasculitis.[50] It is critical to note that FAERS data can show an association but cannot establish causality. These signals require further investigation through rigorous epidemiological studies to determine if a true causal link exists. The potential signal for neurological events like dementia is particularly noteworthy, as a presumed lack of CNS effects is a key theoretical advantage over anticholinergics. The FAERS analysis also found that while the majority of adverse events (56%) had an onset within the first 30 days of treatment, reports of adverse events occurring even after one year of use were possible.[50]

8.4 Summary of Non-Clinical Toxicology Studies

Extensive non-clinical toxicology studies in animals were conducted to support the safety of Mirabegron.

• Carcinogenicity and Genotoxicity: A standard battery of genotoxicity assays found that Mirabegron is not mutagenic or clastogenic. Two-year carcinogenicity studies in rodents did not identify any carcinogenic potential, even at exposures many times higher than those achieved in humans at the maximum recommended dose.[26]
• Reproductive Toxicology: Mirabegron is classified as Pregnancy Category C. In animal studies, adverse developmental effects (e.g., delayed ossification in rats, decreased fetal body weights in rabbits) were observed, but only at exposures significantly greater (≥14-22 times) than the human exposure at the maximum recommended dose. The drug was found to be transferred to rat pups via milk.[26]
• Organ Toxicity: In animal studies, the liver was the organ with the highest drug exposure. However, evidence of hepatotoxicity was only seen at or near lethal doses. At clinically relevant exposures, no significant organ toxicity was observed.[52]

Table 4: Comparative Incidence of Key Adverse Events (Mirabegron vs. Anticholinergics)
Adverse Event	Placebo	Mirabegron 25 mg	Mirabegron 50 mg	Solifenacin 5 mg
Hypertension	7.6%	11.3%	7.5%	(Not typically elevated)
Urinary Tract Infection	1.8%	4.2%	2.9%	3.6%
Headache	3.0%	2.1%	3.2%	(Variable, ~2-4%)
Dry Mouth	2.2% - 2.3%	2.8% - 3.8%	2.8% - 3.4%	~23% - 28%
Constipation	1.2%	1.2%	2.8%	~13% - 15%
Data compiled and synthesized from multiple sources, including prescribing information and clinical trial reports, to represent typical incidences. Solifenacin data is representative of the anticholinergic class. 7

This table visually quantifies the fundamental risk-benefit trade-off in OAB pharmacotherapy. A clinician and patient choosing Mirabegron are accepting a higher risk of increased blood pressure in exchange for a substantially lower risk of the bothersome anticholinergic effects of dry mouth and constipation.

9.0 Clinically Significant Drug-Drug Interactions

The complex metabolism and transport of Mirabegron create a significant potential for drug-drug interactions (DDIs). A thorough understanding of these interactions is essential for its safe clinical use, particularly in patients with polypharmacy. The most critical interaction involves its inhibition of the CYP2D6 enzyme.

9.1 Interaction with CYP2D6 Substrates (The Primary Clinical Concern)

Mirabegron is a moderate inhibitor of the cytochrome P450 2D6 (CYP2D6) isoenzyme.[1] This is its most clinically significant pharmacokinetic property. By inhibiting CYP2D6, Mirabegron can decrease the metabolism and thereby increase the plasma concentrations and potential for toxicity of co-administered drugs that are substrates of this enzyme.

This interaction is of particular concern for CYP2D6 substrates that have a narrow therapeutic index, where a modest increase in exposure can lead to serious adverse events. Therefore, appropriate monitoring and potential dose adjustment of the co-administered drug are necessary when used with Mirabegron. Drugs in this category include:

• Antiarrhythmics: Flecainide and propafenone.[11]
• Antipsychotics: Thioridazine.[11]
• Tricyclic Antidepressants: Desipramine.[11]

The interaction also affects more commonly used drugs, such as the beta-blocker metoprolol, where co-administration with Mirabegron leads to increased exposure.[11] This DDI profile means that a clinician must perform a careful medication review before prescribing Mirabegron. In a patient taking a narrow therapeutic index CYP2D6 substrate, an alternative OAB agent without this interaction, such as an anticholinergic or vibegron, may be a safer choice.

9.2 Interaction with Strong CYP3A4 Inhibitors and Inducers

Mirabegron itself is a substrate of CYP3A4, another major drug-metabolizing enzyme.[25]

• Strong CYP3A4 Inhibitors: Co-administration with strong inhibitors of CYP3A4 (which are often also P-glycoprotein inhibitors), such as ketoconazole, itraconazole, ritonavir, and clarithromycin, can significantly increase the plasma exposure of Mirabegron.[11] In healthy volunteers, the strong inhibitor ketoconazole increased Mirabegron AUC by 1.8-fold.[36] This necessitates a dose reduction of Mirabegron to a maximum of 25 mg once daily in patients with normal renal and hepatic function. Further restrictions apply to patients with renal or hepatic impairment who are also taking strong CYP3A4 inhibitors, where its use may not be recommended.[36]
• CYP3A4 Inducers: Conversely, co-administration with strong CYP3A4 inducers, such as rifampin, can decrease the plasma concentration of Mirabegron. However, this effect is not considered to be of sufficient magnitude to require a routine dose adjustment.[11]

9.3 Interactions with Digoxin, Warfarin, and Other Agents

• Digoxin: Mirabegron is an inhibitor of the P-glycoprotein (P-gp) transporter, for which digoxin is a substrate. Co-administration increases the Cmax​ and AUC of digoxin. The prescribing information explicitly recommends that when initiating combination therapy, the lowest possible dose of digoxin should be prescribed. Serum digoxin concentrations must then be monitored to allow for careful titration of the digoxin dose to the desired clinical effect.[11]
• Warfarin: Clinical studies have shown that Mirabegron does not have a clinically significant effect on the pharmacokinetics or pharmacodynamics (as measured by INR and prothrombin time) of warfarin.[11] No dose adjustment is needed.
• Antimuscarinics: This is a pharmacodynamic interaction. The concurrent use of Mirabegron with antimuscarinic agents (e.g., solifenacin, tolterodine) can lead to an additive risk of urinary retention, especially in patients with pre-existing bladder outlet obstruction. Cautious administration and monitoring are required.[10]

Table 6: Guide to Clinically Significant Drug-Drug Interactions with Mirabegron
Interacting Drug/Class	Mechanism of Interaction	Clinical Effect	Recommended Management
CYP2D6 Substrates (especially with narrow therapeutic index, e.g., flecainide, propafenone, thioridazine, desipramine)	Mirabegron is a moderate CYP2D6 inhibitor. 10	Increased plasma concentrations and potential toxicity of the co-administered drug.	Use with caution. Appropriate monitoring (e.g., ECG, drug levels) and potential dose adjustment of the CYP2D6 substrate may be necessary. Consider alternative OAB therapy. 10
Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin)	Inhibition of CYP3A4-mediated metabolism of Mirabegron. 36	Increased plasma concentrations and potential toxicity of Mirabegron.	Reduce Mirabegron dose to a maximum of 25 mg once daily. Not recommended in patients with severe renal or moderate/severe hepatic impairment. 36
Digoxin	Mirabegron inhibits P-glycoprotein (P-gp), a transporter responsible for digoxin efflux. 11	Increased plasma concentrations and potential toxicity of digoxin.	When initiating, prescribe the lowest dose of digoxin. Monitor serum digoxin concentrations and titrate digoxin dose based on clinical effect. 11
Antimuscarinic Agents (e.g., solifenacin, tolterodine)	Additive pharmacodynamic effects.	Increased risk of urinary retention, especially in patients with Bladder Outlet Obstruction (BOO). 10	Administer with caution. Monitor for signs and symptoms of urinary retention. 10
CYP3A4 Inducers (e.g., rifampin)	Induction of CYP3A4-mediated metabolism of Mirabegron. 36	Decreased plasma concentrations of Mirabegron, potentially reducing efficacy.	No dose adjustment for Mirabegron is generally required. 11

10.0 Dosing, Administration, and Patient Management

10.1 Recommended Dosing Regimens

The dosing of Mirabegron is tailored to the specific indication and patient population.

• Adults with Overactive Bladder (OAB):
• Monotherapy Starting Dose: The recommended starting dose is 25 mg once daily.[10]
• Monotherapy Dose Titration: The 25 mg dose is effective within 8 weeks. Based on individual patient efficacy and tolerability, the dose may be increased to the maximum recommended dose of 50 mg once daily after 4 to 8 weeks of treatment.[10]
• Combination Therapy: When used in combination with solifenacin succinate, the recommended starting dose is Mirabegron 25 mg once daily plus solifenacin 5 mg once daily. The Mirabegron dose may be increased to 50 mg once daily after 4 to 8 weeks, based on efficacy and tolerability.[10]
• Pediatric Patients (NDO, age ≥ 3 years):
• Dosing is based on body weight and is administered using the prolonged-release oral suspension (8 mg/mL).[13]
• Weight 11 to <22 kg: Starting dose is 3 mL (24 mg) once daily; maximum dose is 6 mL (48 mg) once daily.
• Weight 22 to <35 kg: Starting dose is 4 mL (32 mg) once daily; maximum dose is 8 mL (64 mg) once daily.
• Weight ≥35 kg: Starting dose is 6 mL (48 mg) once daily; maximum dose is 10 mL (80 mg) once daily. The 25 mg or 50 mg tablet may also be used in this weight group.[13]

10.2 Guidelines for Administration

Proper administration is crucial for ensuring the efficacy and safety of Mirabegron's extended-release formulations.

• Frequency: Mirabegron should be taken once daily, at approximately the same time each day to maintain consistent plasma levels.[13]
• Tablet Administration: The extended-release tablets must be swallowed whole with a glass of water. They must not be chewed, divided, or crushed, as this would disrupt the controlled-release mechanism, leading to dose dumping and an increased risk of adverse effects.[10]
• Food: Adults may take the tablet with or without food. Pediatric patients should take the oral suspension with food to reduce the risk of side effects like tachycardia.[13]
• Missed Dose: If a dose is missed, the patient should take it as soon as they remember, unless it is more than 12 hours late (i.e., the next scheduled dose is less than 12 hours away). If it is more than 12 hours late, the missed dose should be skipped, and the next dose should be taken at the regular time. Patients should be instructed not to take two doses at once to make up for a missed dose.[13]

10.3 Dose Adjustments for Renal and Hepatic Impairment

Mirabegron clearance is dependent on both renal and hepatic function, requiring specific dose adjustments in patients with impairment.

• Renal Impairment:
• Mild to Moderate (eGFR 30-89 mL/min/1.73 m2): No dose adjustment is necessary.[12]
• Severe (eGFR 15-29 mL/min/1.73 m2): The maximum recommended dose is 25 mg once daily.[10]
• End-Stage Renal Disease (ESRD, eGFR <15 mL/min/1.73 m2) or requiring dialysis: Use is not recommended.[10]
• Hepatic Impairment:
• Mild (Child-Pugh Class A): No dose adjustment is necessary.[41]
• Moderate (Child-Pugh Class B): The maximum recommended dose is 25 mg once daily.[10]
• Severe (Child-Pugh Class C): Use is not recommended.[12]
• Combined Impairment and DDI: Stricter limitations apply when patients with renal or hepatic impairment are also taking strong CYP3A4 inhibitors. For example, use is not recommended in patients with severe renal impairment who are also taking a strong CYP3A4 inhibitor.[36]

10.4 Patient Counseling and Monitoring Parameters

Effective patient management involves clear counseling and routine monitoring.

• Counseling Points: Patients should be counseled on the importance of swallowing the tablet whole, the proper missed-dose procedure, and the fact that it may take up to 8 weeks to experience the full therapeutic benefit.[13] They should be informed about the potential side effects and instructed to report any serious symptoms immediately.
• Monitoring Parameters:
• Blood Pressure: Blood pressure should be checked at baseline and monitored periodically throughout treatment, especially in patients with a history of hypertension.[10]
• Symptoms of Angioedema: Patients should be advised to seek immediate medical attention if they experience swelling of the face, lips, tongue, or throat, or have difficulty breathing.[14]
• Urinary Symptoms: Patients should be instructed to report any new or worsening difficulty in urinating, a weak urine stream, or a feeling of incomplete bladder emptying, which could be signs of urinary retention.[14]
• Efficacy: The patient's response to therapy should be assessed after 4-8 weeks to determine if a dose increase from 25 mg to 50 mg is warranted.[10]

Table 5: Dosing Recommendations and Adjustments for Special Populations
Patient Population	Starting Dose	Maximum Dose	Special Considerations
Adult OAB (Normal Function)	25 mg once daily	50 mg once daily	May increase dose after 4-8 weeks based on efficacy/tolerability. 10
Pediatric NDO (by weight)	3-6 mL (24-48 mg) once daily	6-10 mL (48-80 mg) once daily	Dose is weight-based using oral suspension. Must be taken with food. 13
Severe Renal Impairment (eGFR 15-29)	25 mg once daily	25 mg once daily	Dose increase is not recommended. 10
ESRD (eGFR <15) / Dialysis	Not Recommended	Not Recommended	Insufficient data to support safe use. 10
Moderate Hepatic Impairment (Child-Pugh B)	25 mg once daily	25 mg once daily	Dose increase is not recommended. 10
Severe Hepatic Impairment (Child-Pugh C)	Not Recommended	Not Recommended	Not studied in this population. 12
Concomitant use with Strong CYP3A4 Inhibitors	25 mg once daily	25 mg once daily	Further restrictions apply if patient also has renal/hepatic impairment. 36

11.0 Global Regulatory and Commercial Overview

The regulatory journey of Mirabegron reflects a well-executed lifecycle management strategy, beginning with a core indication and methodically expanding to include combination therapy and a special pediatric population.

11.1 FDA Approval Timeline and Key Milestones (US Market)

The development and approval process in the United States, overseen by the FDA, followed a clear timeline:

• August 29, 2011: Astellas Pharma announced the submission of the New Drug Application (NDA) for Mirabegron to the FDA.[2]
• June 28, 2012: The FDA granted its initial approval for Myrbetriq® (mirabegron) extended-release tablets for the treatment of OAB in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. This marked the introduction of the first β3-adrenergic agonist for this indication.[2] The drug became available in U.S. pharmacies in October 2012.[55]
• May 7, 2018: The FDA approved a supplemental NDA (sNDA) for the use of Myrbetriq® in combination with the antimuscarinic agent solifenacin succinate (Vesicare®). This approval was based on data from the SYNERGY and BESIDE trials and provided an evidence-based option for patients with an inadequate response to monotherapy.[2]
• March 25, 2021: The FDA approved both a new indication and a new product formulation. Myrbetriq® and the newly formulated Myrbetriq Granules® were approved for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older, addressing a significant unmet need in this population.[1]

This stepwise expansion of the drug's label—from a foundational adult monotherapy indication to combination use and finally to a specialized pediatric indication with a new formulation—demonstrates a strategic approach to maximizing the clinical and commercial value of the asset over its lifecycle.

11.2 EMA Approval and European Market Context

Mirabegron underwent a parallel regulatory review process in Europe under the oversight of the European Medicines Agency (EMA).

• December 20, 2012: The drug was first registered for the European market under the brand name Betmiga®.[56]
• January 11, 2013: The European Commission granted formal marketing authorization for Betmiga® for the symptomatic treatment of urgency, increased micturition frequency, and/or urgency incontinence in adult patients with OAB syndrome.[16]
• The European indication has since been expanded to include the treatment of NDO in children and adolescents aged 3 to less than 18 years.[28]
• Post-marketing surveillance by the EMA has been active. Following a cumulative review of safety data, the EMA issued new recommendations and updated the product information to strengthen the warnings regarding the risk of increased blood pressure and to contraindicate its use in patients with severe uncontrolled hypertension.[48]

11.3 Global Brand Names and Generic Availability

Mirabegron is marketed globally under several distinct brand names, reflecting regional marketing strategies by Astellas Pharma.

• Brand Names: The most common brand names are Myrbetriq® in the United States, Betmiga® in the European Union and the United Kingdom, and Betanis® in Japan.[9]
• Generic Status: The patent protection for Mirabegron has begun to expire, leading to the approval of generic versions. In the United States, the FDA has approved generic mirabegron extended-release tablets from several manufacturers, including Lupin Ltd, Zydus Pharmaceuticals, and Alkem Laboratories.[27] The availability of a lower-cost generic option is expected to increase access to the medication, though market entry can be influenced by remaining patents and exclusivity periods.[9] In 2022, Mirabegron was the 222nd most commonly prescribed medication in the United States, with over 1 million prescriptions filled.[9]

12.0 Synthesis and Expert Recommendations

12.1 Integrated Assessment of Mirabegron's Risk-Benefit Profile

Mirabegron has established itself as a cornerstone in the management of OAB and pediatric NDO, primarily by offering a distinct and favorable risk-benefit profile compared to the long-established antimuscarinic class. Its core clinical benefit is the provision of effective OAB symptom control, with a magnitude of effect comparable to that of standard anticholinergics, for a population of patients who are often unable to tolerate traditional therapy. The complementary mechanism of action also provides a strong rationale for its use in combination therapy for refractory cases.

This benefit must be weighed against a well-defined set of risks. The primary safety concerns are adrenergic in nature and are a direct consequence of its mechanism of action. These include dose-dependent increases in blood pressure and heart rate, which necessitate careful patient selection and monitoring. The risk of rare but serious angioedema, while low, requires immediate recognition and drug discontinuation. From a clinical pharmacology standpoint, the most significant risk is its potential for drug-drug interactions stemming from its role as a moderate inhibitor of CYP2D6, which complicates its use in the context of polypharmacy, particularly with narrow therapeutic index drugs.

Overall, for a properly selected patient—one without severe uncontrolled hypertension, significant bladder outlet obstruction, or conflicting medications—the risk-benefit profile of Mirabegron is highly favorable. It successfully addresses the most common reason for treatment failure with antimuscarinics: intolerable side effects.

12.2 Positioning in Clinical Practice: First-Line vs. Second-Line Therapy

The positioning of Mirabegron in clinical guidelines has evolved as experience with the drug has grown. It is now firmly established as a first-line pharmacotherapy option for OAB, alongside antimuscarinic agents. The choice between these two classes for a treatment-naïve patient should be guided by an individualized assessment of their comorbidities and risk factors.

• Mirabegron is a particularly strong first-line choice for patients in whom anticholinergic side effects are highly undesirable or pose a significant risk. This includes elderly patients who are at higher risk for cognitive impairment and falls, patients with a history of significant constipation, and those who are concerned about or have previously experienced dry mouth with other medications.
• Mirabegron is the definitive second-line therapy for patients who have previously tried an antimuscarinic agent and discontinued it due to poor tolerability.
• Combination therapy with Mirabegron and an antimuscarinic like solifenacin represents a key third-line option for patients who are refractory to monotherapy, offering a proven, evidence-based strategy to improve symptom control before escalating to more invasive treatments such as onabotulinumtoxinA injections or sacral neuromodulation.

12.3 Recommendations for Clinical Use and Future Research Directions

Clinical Recommendations:

1. Patient Selection is Paramount: Before initiating Mirabegron, clinicians must perform a thorough patient assessment, including a baseline blood pressure measurement, a review of comorbidities (especially cardiovascular disease and risk of BOO), and a comprehensive medication reconciliation to screen for potential DDIs.
2. Mandatory DDI Check: Given its status as a moderate CYP2D6 inhibitor, a check for interactions with co-administered drugs is non-negotiable. Particular caution is required for patients on narrow therapeutic index CYP2D6 substrates (e.g., flecainide, thioridazine) and P-gp substrates (e.g., digoxin).
3. Active Monitoring: Blood pressure should be monitored periodically after initiating therapy. Patients should be counseled on the signs of angioedema and urinary retention and instructed to report them immediately.
4. Patient-Centered Decision Making: The choice between Mirabegron and an antimuscarinic should be a shared decision, discussing the trade-offs between the risk of hypertension with Mirabegron and the risk of anticholinergic side effects with the alternative.

Future Research Directions:

1. Long-Term Cardiovascular Safety: While trial data are reassuring, large-scale, long-term observational studies are needed to definitively characterize the cardiovascular safety of chronic Mirabegron use in a real-world population, especially in patients with baseline cardiovascular risk factors.
2. Investigation of Post-Marketing Signals: The potential safety signals for neurological events (dementia, TIA, Parkinson's disease) identified in the FAERS database are concerning and warrant rigorous investigation through well-designed epidemiological studies to either refute or confirm a causal association.
3. Exploration of Metabolic Effects: The preclinical and early clinical evidence of BAT activation is compelling. Further research is needed to understand the long-term metabolic consequences (e.g., on weight, glucose homeostasis, lipid profiles) of Mirabegron treatment in OAB patients and to explore its potential as a primary therapy for metabolic disorders.
4. Comparative Effectiveness in Refractory OAB: As the treatment landscape evolves, head-to-head clinical trials comparing the efficacy and safety of combination therapy (e.g., Mirabegron + solifenacin) versus newer monotherapies (e.g., Vibegron) would be highly valuable to guide optimal treatment sequencing for patients who fail initial monotherapy.

Works cited

1. Mirabegron | C21H24N4O2S | CID 9865528 - PubChem, accessed July 22, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Mirabegron
2. Myrbetriq (mirabegron) FDA Approval History - Drugs.com, accessed July 22, 2025, https://www.drugs.com/history/myrbetriq.html
3. FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms - PR Newswire, accessed July 22, 2025, https://www.prnewswire.com/news-releases/fda-approves-supplemental-new-drug-application-for-myrbetriq-mirabegron-for-use-in-combination-with-solifenacin-succinate-for-the-treatment-of-overactive-bladder-symptoms-300644079.html
4. Beta3-adrenergic agonist - Wikipedia, accessed July 22, 2025, https://en.wikipedia.org/wiki/Beta3-adrenergic_agonist
5. Mechanism of Action | MYRBETRIQ® (mirabegron ER tablets), accessed July 22, 2025, https://www.myrbetriqhcp.com/mechanism-of-action/
6. A β3 Agonist, Mirabegron for the Treatment of Overactive Bladder - UroToday, accessed July 22, 2025, https://www.urotoday.com/volume-4-2011/vol-4-issue-6/48744-a-3-agonist-mirabegron-for-the-treatment-of-overactive-bladder.html
7. ICS 2021 Abstract #405 Comparison between Anticholinergic and Beta-3-adrenergic receptor agonist (Mirabegron) in Overactive Bladder-A systemic review - International Continence Society, accessed July 22, 2025, https://www.ics.org/2021/abstract/405
8. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis - Revista Brasileira de Ginecologia e Obstetrícia, accessed July 22, 2025, https://journalrbgo.org/article/mirabegron-and-anticholinergics-in-the-treatment-of-overactive-bladder-syndrome-a-meta-analysis/
9. Mirabegron - Wikipedia, accessed July 22, 2025, https://en.wikipedia.org/wiki/Mirabegron
10. Myrbetriq - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed July 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202611s011lbl.pdf
11. Drug Interactions | MYRBETRIQ® (mirabegron ER tablets), accessed July 22, 2025, https://www.myrbetriqhcp.com/dosing/drug-interactions/
12. Mirabegron - StatPearls - NCBI Bookshelf, accessed July 22, 2025, https://www.ncbi.nlm.nih.gov/books/NBK538513/
13. Myrbetriq (mirabegron): Uses, Side Effects, Dosage & More - GoodRx, accessed July 22, 2025, https://www.goodrx.com/myrbetriq/what-is
14. Mirabegron: MedlinePlus Drug Information, accessed July 22, 2025, https://medlineplus.gov/druginfo/meds/a612038.html
15. FDA Approves Overactive Bladder Treatment Myrbetriq™ (mirabegron) from Astellas, accessed July 22, 2025, https://newsroom.astellas.us/2012-06-28-FDA-Approves-Overactive-Bladder-Treatment-Myrbetriq-mirabegron-from-Astellas
16. new class of treatment for overactive bladder approved in europe - Astellas Pharma Inc., accessed July 22, 2025, https://www.astellas.com/en/news/12326
17. Comparison of efficacy and safety of mirabegron and vibegron in the treatment of Overactive Bladder (OAB) in older women: A systematic review and meta-analysis | PLOS One - Research journals, accessed July 22, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0317550
18. On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder - PMC, accessed July 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5380826/
19. CAS 223673-61-8 Mirabegron - BOC Sciences, accessed July 22, 2025, https://www.bocsci.com/product/mirabegron-cas-223673-61-8-182334.html
20. Mirabegron | 223673-61-8 - ChemicalBook, accessed July 22, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB22493967.htm
21. Mirabegron 223673-61-8 | Tokyo Chemical Industry (India) Pvt. Ltd., accessed July 22, 2025, https://www.tcichemicals.com/IN/en/p/M3567
22. Mirabegron | CAS#:223673-61-8 | Chemsrc, accessed July 22, 2025, https://www.chemsrc.com/en/cas/223673-61-8_1170692.html
23. Mirabegron | CAS 223673-61-8 | SCBT - Santa Cruz Biotechnology, accessed July 22, 2025, https://www.scbt.com/p/mirabegron-223673-61-8
24. Mirabegron (YM-178, CAS Number: 223673-61-8) | Cayman Chemical, accessed July 22, 2025, https://www.caymanchem.com/product/17319/mirabegron
25. Mirabegron: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 22, 2025, https://go.drugbank.com/drugs/DB08893
26. 202611Orig1s000 - accessdata.fda.gov, accessed July 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000SumR.pdf
27. Generic Myrbetriq Availability - Drugs.com, accessed July 22, 2025, https://www.drugs.com/availability/generic-myrbetriq.html
28. Betmiga | European Medicines Agency (EMA), accessed July 22, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga
29. Mirabegron Extended-release Oral Tablets - Cleveland Clinic, accessed July 22, 2025, https://my.clevelandclinic.org/health/drugs/19467-mirabegron-extended-release-oral-tablets
30. Mirabegron (oral route) - Side effects & dosage - Mayo Clinic, accessed July 22, 2025, https://www.mayoclinic.org/drugs-supplements/mirabegron-oral-route/description/drg-20075675
31. Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug, accessed July 22, 2025, https://www.mdpi.com/2077-0383/12/21/6897
32. What is the mechanism of action of Myrbetriq (Mirabegron)? - Dr.Oracle, accessed July 22, 2025, https://www.droracle.ai/articles/7210/what-is-the-mechanism-of-action-for-myrbetrig
33. About mirabegron - NHS, accessed July 22, 2025, https://www.nhs.uk/medicines/mirabegron/about-mirabegron/
34. Overactive Bladder (OAB) Medication | Myrbetriq (mirabegron ER tablets), accessed July 22, 2025, https://www.myrbetriq.com/
35. (PDF) Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis - ResearchGate, accessed July 22, 2025, https://www.researchgate.net/publication/372649207_Mirabegron_and_Anticholinergics_in_the_Treatment_of_Overactive_Bladder_Syndrome_A_Meta-analysis
36. Betmiga, INN-mirabegron - EMA, accessed July 22, 2025, https://www.ema.europa.eu/en/documents/product-information/betmiga-epar-product-information_en.pdf
37. MYRBETRIQ® (mirabegron ER tablets) | For Healthcare Professionals, accessed July 22, 2025, https://www.myrbetriqhcp.com/
38. Annotation of EMA Label for mirabegron and CYP2D6 - PharmGKB, accessed July 22, 2025, https://www.pharmgkb.org/labelAnnotation/PA166183219
39. Drugs@FDA: Drug Product Myrbetriq (mirabegron), NDA202611, Astellas Pharma US, Inc., accessed July 22, 2025, https://www.pharmgkb.org/literature/15101938
40. Annotation of FDA Label for mirabegron and CYP2D6 - PharmGKB, accessed July 22, 2025, https://www.pharmgkb.org/labelAnnotation/PA166177514
41. Mirabegron Monograph for Professionals - Drugs.com, accessed July 22, 2025, https://www.drugs.com/monograph/mirabegron.html
42. FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms - the Astellas US Newsroom, accessed July 22, 2025, https://newsroom.astellas.us/2018-05-07-FDA-Approves-Supplemental-New-Drug-Application-for-Myrbetriq-R-mirabegron-for-Use-in-Combination-with-solifenacin-succinate-for-the-Treatment-of-Overactive-Bladder-Symptoms
43. www.mayoclinic.org, accessed July 22, 2025, https://www.mayoclinic.org/drugs-supplements/mirabegron-oral-route/description/drg-20075675#:~:text=Mirabegron%20is%20used%20alone%20or,neurogenic%20detrusor%20overactivity%20(NDO).
44. Mirabegron versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review - Beyond the Abstract - UroToday, accessed July 22, 2025, https://www.urotoday.com/recent-abstracts/pelvic-health-reconstruction/overactive-bladder/158704-mirabegron-versus-placebo-and-other-therapeutic-modalities-in-the-treatment-of-patients-with-overactive-bladder-syndrome-a-systematic-review-beyond-the-abstract.html
45. Enuresis, Nocturnal Recruiting Phase Trials for Mirabegron (DB08893) | DrugBank Online, accessed July 22, 2025, https://go.drugbank.com/indications/DBCOND0105171/clinical_trials/DB08893?status=recruiting
46. Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis | Journal of Urology, accessed July 22, 2025, https://www.auajournals.org/doi/10.1097/JU.0000000000001440
47. Gemtesa vs. Myrbetriq: How Do They Compare? - GoodRx, accessed July 22, 2025, https://www.goodrx.com/conditions/overactive-bladder/gemtesa-vs-myrbetriq
48. Mirabegron (Betmiga ) - GOV.UK, accessed July 22, 2025, https://assets.publishing.service.gov.uk/media/561cda83ed915d39bc000011/Betmiga_DHPC_UK_FINAL_MHRA_approved_to_HCPs_04Sept15.pdf
49. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database - Frontiers, accessed July 22, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1376535/full
50. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event - Frontiers, accessed July 22, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1376535/pdf
51. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database - PubMed, accessed July 22, 2025, https://pubmed.ncbi.nlm.nih.gov/38562462/
52. 202611Orig1s000 - accessdata.fda.gov, accessed July 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000PharmR.pdf
53. Taking mirabegron with other medicines and herbal supplements - NHS, accessed July 22, 2025, https://www.nhs.uk/medicines/mirabegron/taking-mirabegron-with-other-medicines-and-herbal-supplements/
54. Drug Approval Package: Brand Name (Generic Name) NDA # - accessdata.fda.gov, accessed July 22, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000TOC.cfm
55. MYRBETRIQ™ (mirabegron), Overactive Bladder Treatment from Astellas, Now Available Through U.S. Pharmacies - Oct 22, 2012, accessed July 22, 2025, https://newsroom.astellas.us/2012-10-22-MYRBETRIQ-mirabegron-Overactive-Bladder-Treatment-from-Astellas-Now-Available-Through-U-S-Pharmacies
56. 3-7-2015 Mirabegron (Betmiga®) was registered for the European market on 20 December 2012. It is indicated for the treatment of - Lareb, accessed July 22, 2025, https://www.lareb.nl/media/mvipc1ir/kwb_2015_2_mirabegron.pdf
57. Mirabegron: medicine to treat the symptoms of an overactive bladder - NHS, accessed July 22, 2025, https://www.nhs.uk/medicines/mirabegron/